Related references
Note: Only part of the references are listed.EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma
Linwah Yip et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients
Ralph Tiedt et al.
CANCER RESEARCH (2011)
Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032
Elisabetta Vergani et al.
NEOPLASIA (2011)
SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data
Bruno Zeitouni et al.
BIOINFORMATICS (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
Ultan McDermott et al.
CANCER RESEARCH (2010)
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Virna Cepero et al.
CANCER RESEARCH (2010)
Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors
Andrea Bertotti et al.
CLINICAL CANCER RESEARCH (2010)
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
Simona Corso et al.
MOLECULAR CANCER (2010)
MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis
Naoto Tsuchiya et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Nallasivam Palanisamy et al.
NATURE MEDICINE (2010)
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
D. Ercan et al.
ONCOGENE (2010)
Staphylococcal Nuclease Domain-Containing Protein 1 as a Potential Tissue Marker for Prostate Cancer
Hidetoshi Kuruma et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Klaus P. Hoeflich et al.
CLINICAL CANCER RESEARCH (2009)
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Sohrab P. Shah et al.
NATURE (2009)
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Pasi A. Jaenne et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
Andrea Bertotti et al.
SCIENCE SIGNALING (2009)
Estimation and assessment of raw copy numbers at the single locus level
H. Bengtsson et al.
BIOINFORMATICS (2008)
Profiling the HeLa S3 transcriptome using randomly primed cDNA and massively parallel short-read sequencing
Ryan D. Morin et al.
BIOTECHNIQUES (2008)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Velvet: Algorithms for de novo short read assembly using de Bruijn graphs
Daniel R. Zerbino et al.
GENOME RESEARCH (2008)
BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma:: A 15-year median follow-up study
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
Thomas Bachleitner-Hofmann et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Structural and functional insights into human Tudor-SN, a key component linking RNA interference and editing
Chia-Lung Li et al.
NUCLEIC ACIDS RESEARCH (2008)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Ultan McDermott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis
Naoto Tsuchiya et al.
CANCER RESEARCH (2007)
Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital Melanocytic Nevi
Barbara Dessars et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
Alan P. Brown et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Lung cancer cell lines harboring MET gene amplification are dependent on met for growth and survival
Bart Lutterbach et al.
CANCER RESEARCH (2007)
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Mechanisms of drug inhibition of signalling molecules
Judith S. Sebolt-Leopold et al.
NATURE (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status
Wei Qi Li et al.
MOLECULAR CANCER (2006)
The Brn-2 transcription factor links activated BRAF to melanoma proliferation
J Goodall et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
BRAF mutations in conjunctival melanoma
J Gear et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2004)
A model-based background adjustment for oligonucleotide expression arrays
ZJ Wu et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2004)
Quantifying single gene copy number by measuring fluorescent probe lengths on combed genomic DNA
J Herrick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
